Hill, Philipp; Zellmann, Felix; Vukova, Tsvetomira et al.
Dose response to methylating agents in the gamma H2AX, SCE and colony formation assays: Effect of MGMT and MPG overexpressionMUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS. Bd. 876. 2022
Saurin, Sabrina; Meineck, Myriam; Erkel, Gerhard et al.
Drug Candidates for Autoimmune DiseasesPHARMACEUTICALS. Bd. 15. H. 5. 2022
Wolf, Jan; Mitka, ?; Hubalewska-Dydejczyk, Alicja et al.
Drug safety in thyroid eye disease - a systematic reviewEXPERT OPINION ON DRUG SAFETY. Bd. 21. H. 7. 2022 S. 881-912
Fiess, Achim; Hufschmidt-Merizian, Clara; Gissler, Sandra et al.
Dry Eye Parameters and Lid Geometry in Adults Born Extremely, Very, and Moderately Preterm with and without ROP: Results from the Gutenberg Prematurity Eye StudyJOURNAL OF CLINICAL MEDICINE. Bd. 11. H. 10. 2022
Hoeing, Alexander; Struth, Robin; Beuck, Christine et al.
Dual activity inhibition of threonine aspartase 1 by a single bisphosphate ligandRSC ADVANCES. Bd. 12. H. 53. 2022 S. 34176-34184
Hebestreit, Helge; Zeidler, Cornelia; Schippers, Christopher et al.
Dual guidance structure for evaluation of patients with unclear diagnosis in centers for rare diseases (ZSE-DUO): study protocol for a controlled multi-center cohort studyORPHANET JOURNAL OF RARE DISEASES. Bd. 17. H. 1. 2022
Willems, Loes H.; Thijssen, Dick H. J.; Groh, Laszlo A. et al.
Dual pathway inhibition as compared to acetylsalicylic acid monotherapy in relation to endothelial function in peripheral artery disease, a phase IV clinical trialFRONTIERS IN CARDIOVASCULAR MEDICINE. Bd. 9. 2022
Karl, Martin; Hasselwander, Solveig; Zhou, Yawen et al.
Dual roles of B lymphocytes in mouse models of diet-induced nonalcoholic fatty liver diseaseHEPATOLOGY. Bd. 76. H. 4. 2022 S. 1135-1149
Herz, Damian M.; Bange, Manuel; Gonzalez-Escamilla, Gabriel et al.
Dynamic control of decision and movement speed in the human basal gangliaNATURE COMMUNICATIONS. Bd. 13. H. 1. 2022
Tonner, Henrik; Hunn, Selina; Auler, Nadine et al.
Dynamin-like Protein 1 (DNML1) as a Molecular Target for Antibody-Based Immunotherapy to Treat GlaucomaINTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. Bd. 23. H. 21. 2022